Vor Biopharma Inc. VOR
Vor Biopharma Inc. (Nasdaq: VOR) is an immunology/inflammation drug developer. Its lead program, Telitacicept (licensed from RemeGen, ex-Greater China rights), is in Phase 3 for Generalized myasthenia gravis (global Phase 3); Sjögren's disease (global Phase 3).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Telitacicept, global Phase 3 | Generalized myasthenia gravis | protein/peptide | Phase 3 |
| Telitacicept, global Phase 3 | Sjögren's disease (first patient dosed March 2026) | protein/peptide | Phase 3 |
| Trem-cel (VOR33) and VCAR33 | Hematologic malignancies; program spend decreased in 2026 | cell therapy | Phase 1 |
Recent results and decisions
- Jun 8, 2026approval China NMPA conditionally approved telitacicept for IgAN (ex-US); supporting Phase 3 TELIGAN showed 59% UPCR reduction at Week 39 (55% placebo-adjusted).
China’s National Medicinal Products Administration (NMPA) has conditionally approved telitacicept for the treatment of adult patients with IgAN.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.